Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

References

• Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Seminars in Oncology 1992; 19(3)244–253
   PubMed Web of Science ®Google Scholar
• Gasparini, G, Gullick, WJ, Bevilacqua, P, et al. Human breast cancer: Prognostic significance of the expression of the cerbB2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992; 10: 686–695
   PubMed Web of Science ®Google Scholar
• McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node negative breast cancer. N Engl J Med June, 1992; 1756–1761, 25
   PubMed Web of Science ®Google Scholar
• Neville, AM, Bettelheim, R, Gelber, RD, et al. Factors predicting treatment responsiveness and prognosis in node negative breast cancer. J Clin Oncol 1992; 10: 696–705
   PubMed Web of Science ®Google Scholar
• Slamon, DJ, Godolphin, W, Jones, LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarina cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Slamon, DJ, Clark, GM, Wong, SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER -2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359–377
   PubMed Web of Science ®Google Scholar
• Sambrook J, Fritsch EF, Maniatis T. Molecular cloning — A laboratory manual. New York: Cold Spring Harbor Laboratory Press 1989; 1: 5.31–5.31
   Google Scholar
• King C, Kraus M, Aaronson S. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974–974
   PubMed Web of Science ®Google Scholar
• Felix, C, Poplack, D, Reaman, G, et al. Characterisation of immunoglobulin and T cell receptor gene patterns in B cell precursor acute lymphoblastic leukaemia of childhood. J Clin Oncol 1990; 8(3)431–442
   PubMed Web of Science ®Google Scholar
• Berger, MS, Locher, GW, Saurers, S, et al. Correlation of cerbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Ca Research 1988; 48: 1238–1243
   PubMed Web of Science ®Google Scholar
• Guerin, M, Gabillot, M, Mathieu, MC, et al. Structure and expression of cerbB2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989; 43: 201–208
   PubMed Web of Science ®Google Scholar
• Lacroix, H, Inglehart, JD, Sleiner, MA, et al. Over-expression of cerbB2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumours and regional metastases. Oncogene 1989; 4: 145–151
   PubMed Web of Science ®Google Scholar
• Mori, S, Akiyama, T, Morishita, Y, et al. Light and electron microscopical demonstration of cerbB2 gene product-like immunoreactivity in human malignant tumours. Virchows Arch B 1987; 54: 8–15
   Google Scholar
• Paterson, MC, Dietrich, KD, Danyluk, J, et al. Correlation between cerbB2 amplification and risk of recurrent disease in node-negative breast cancer. Ca Research 1991; 51: 556–567
   PubMed Web of Science ®Google Scholar
• Van de Vijver, MJ, Mooi, WJ, Wirman, P, et al. Immunohistochemical detection of the new protein in tissue sections of human breast tumours with amplified neu DNA. Oncogene 1988; 2: 175–178
   PubMed Web of Science ®Google Scholar
• Thor, AD, Schwartz, LH, Koerner, FC, et al. Analysis of cerbB2 expression in breast carcinomas with clinical follow-up. Cancer Research 1989; 49: 7147–7152
   PubMed Web of Science ®Google Scholar
• Ali, IU, Campbell, G, Liderau, R, et al. Lack of evidence for the prognostic significance of cerbB2 amplification in human breast carcinoma. Oncogene Research 1988; 3: 139–146
   PubMedGoogle Scholar
• Allred, D, Clark, G, Tandon, A, et al. HER-2/neu expression identified a group of node negative breast cancer patients at high risk of recurrence. Proc Am Soc Clin Oncol 1990; 9: 23–23, (abstr)
   Google Scholar
• Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Seminars in Oncology 1992; 19(3)244–253
   PubMed Web of Science ®Google Scholar
• Paik, S, King, CR, Simpson, S, et al. Quantification of cerbB2/neu levels in tissue. Methods in Enzymology 1991; 198: 290–300
   PubMed Web of Science ®Google Scholar
• Ali, IU, Campbell, G, Liderau, R, et al. Amplification of cerbB2 and aggressive human breast tumours?. Science 1988; 240: 1795–1796
   PubMed Web of Science ®Google Scholar
• Fontaine, J, Tesseraux, M, Klein, V, et al. Gene amplification and expression of the neu (cerbB2) sequence in human mammary carcinoma. Oncology 1988; 45: 360–363
   PubMed Web of Science ®Google Scholar
• Venter, DJ, Kumar, S, Tuzi, NL, et al. Over-expression of the cerbB2 oncoprotein in human breast carcinomas: immunohistological assessment correlated with gene amplification. Lancet July, 1987; 69–72, 11
   PubMed Web of Science ®Google Scholar
• Wolman, SR, Pauley, RJ, Mohamed, AN, et al. Genetic markers as prognostic indicators in breast cancer. Cancer 1992; 70: 1765–1767
   PubMed Web of Science ®Google Scholar
• De Potter, CR, Beghin, C, Makar, AP, et al. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 1990; 45: 55–58
   PubMed Web of Science ®Google Scholar
• Van de Vijver, MJ, Peterse, JL, Mooi, WJ, et al. Neu protein over-expression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239–1245
   PubMed Web of Science ®Google Scholar
• Winstanley, J, Cooke, T, Murray, GD, et al. The long term prognostic significance of cerbB2 in primary breast cancer. Br J Cancer 1991; 63: 447–450
   PubMed Web of Science ®Google Scholar
• Barbareschi, M, Leonardi, E, Mauri, FA, et al. p53 and cerbB2 protein expression in breast carcinomas. Am J Clin Pathol 1992; 98: 408–418
   PubMed Web of Science ®Google Scholar
• Gusterson, BA, Machin, LG, Gullick, WJ, et al. Immunohistochemical distribution of cerbB2 in infiltrating and in situ breast cancer. Int J Cancer 1988; 42: 842–845
   PubMed Web of Science ®Google Scholar
• Dawkins, HJS, Robbins, PD, Sarna, M, et al. cerbB2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, Slot blot, ELISA and immunohistochemistry. Pathology 1993; 25: 124–132
   PubMed Web of Science ®Google Scholar